دورية أكاديمية
أعرض في EDS

Caspase-4 in glioma indicates deterioration and unfavorable prognosis by affecting tumor cell proliferation and immune cell recruitment.

التفاصيل البيبلوغرافية
العنوان: Caspase-4 in glioma indicates deterioration and unfavorable prognosis by affecting tumor cell proliferation and immune cell recruitment.
المؤلفون: Di L; School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China., Li M; Guangdong Key Laboratory of Genomic Instability and Human Disease Prevention, Department of Biochemistry and Molecular Biology, School of Medicine, Shenzhen University, Shenzhen, 518055, China., Lei X; Department of Biochemistry and Biophysics, School of Basic Medical Sciences, Faculty of Medicine, Peking University, Beijing, 100191, China., Xie W; Department of Clinical Laboratory, Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China., Liu G; Department of Clinical Laboratory, Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China., Wang Y; Division of Rheumatology and Immunology, University of Toledo Medical Center, Toledo, OH, 43614, USA., Zhang W; Department of Clinical Laboratory, Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang, China. wenjingzhang@hrbmu.edu.cn., Zhu WG; School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China. zhuweiguo@szu.edu.cn.; Guangdong Key Laboratory of Genomic Instability and Human Disease Prevention, Department of Biochemistry and Molecular Biology, School of Medicine, Shenzhen University, Shenzhen, 518055, China. zhuweiguo@szu.edu.cn.; College of Basic Medical Sciences, Wan Nan Medical College, Wuhu, 241006, China. zhuweiguo@szu.edu.cn.; International Cancer Center, School of Medicine, Shenzhen University, Shenzhen, 518055, China. zhuweiguo@szu.edu.cn.
المصدر: Scientific reports [Sci Rep] 2024 Jul 29; Vol. 14 (1), pp. 17443. Date of Electronic Publication: 2024 Jul 29.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Glioma*/genetics , Glioma*/pathology , Glioma*/immunology , Cell Proliferation* , Brain Neoplasms*/genetics , Brain Neoplasms*/pathology , Brain Neoplasms*/immunology , Brain Neoplasms*/mortality , Gene Expression Regulation, Neoplastic* , Caspases, Initiator*/metabolism , Caspases, Initiator*/genetics, Humans ; Prognosis ; Pyroptosis/genetics ; Protein Interaction Maps ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Kaplan-Meier Estimate ; Cell Line, Tumor
مستخلص: Gliomas are the most common malignant tumors of the central nervous system, accounting for approximately 80% of all malignant brain tumors. Accumulating evidence suggest that pyroptosis plays an essential role in the progression of cancer. Unfortunately, the effect of the pyroptosis-related factor caspase-4 (CASP4) on immunotherapy and drug therapy for tumors has not been comprehensively investigated. In this study, we systematically screened six hub genes by pooling differential pyroptosis-related genes in The Cancer Genome Atlas (TCGA) glioma data and the degree of centrality of index-related genes in the protein-protein interaction network. We performed functional and pathway enrichment analyses of the six hub genes to explore their biological functions and potential molecular mechanisms. We then investigated the importance of CASP4 using Kaplan-Meier survival analysis of glioma patients. TCGA and the Chinese Glioma Genome Atlas (CGGA) databases showed that reduced CASP4 expression leads to the potent clinical deterioration of glioma patients. Computational analysis of the effect of CASP4 on the infiltration level and recruitment of glioma immune cells revealed that CASP4 expression was closely associated with a series of tumor-suppressive immune checkpoint molecules, chemokines, and chemokine receptors. We also found that aberrant CASP4 expression correlated with chemotherapeutic drug sensitivity. Finally, analysis at the cellular and tissue levels indicated an increase in CASP4 expression in glioma, and that CASP4 inhibition significantly inhibited the proliferation of glioma cells. Thus, CASP4 is implicated as a new prognostic biomarker for gliomas with the potential to further guide immunotherapy and chemotherapy strategies for glioma patients.
(© 2024. The Author(s).)
References: Nat Rev Cancer. 2020 Apr;20(4):203-217. (PMID: 32161398)
Cancer Res. 2022 Sep 16;82(18):3321-3334. (PMID: 35841593)
Mol Cell. 2018 Jul 19;71(2):201-215.e7. (PMID: 30029001)
J Mol Cell Biol. 2019 Jun 1;11(6):496-508. (PMID: 30321352)
Cancer Cell Int. 2022 Apr 7;22(1):144. (PMID: 35392903)
Immunobiology. 2018 Apr - May;223(4-5):356-364. (PMID: 29113699)
Hum Mol Genet. 2016 Oct 1;25(19):4315-4327. (PMID: 27516385)
Adv Mater. 2019 Dec;31(51):e1904364. (PMID: 31659802)
Semin Cancer Biol. 2018 Aug;51:50-58. (PMID: 29170066)
Oncotarget. 2018 Apr 10;9(27):19065-19078. (PMID: 29721184)
Immunity. 2019 Jun 18;50(6):1352-1364. (PMID: 31216460)
Int J Mol Sci. 2018 Jul 24;19(8):. (PMID: 30042333)
Endocr Relat Cancer. 2018 Jul;25(7):R421-R434. (PMID: 29760166)
Nat Immunol. 2022 Aug;23(8):1148-1156. (PMID: 35879449)
Cancer Cell. 2019 Apr 15;35(4):692-704.e12. (PMID: 30905762)
Front Immunol. 2022 Aug 05;13:963582. (PMID: 35990672)
Int J Mol Sci. 2021 Aug 19;22(16):. (PMID: 34445646)
Mol Cancer. 2022 Apr 27;21(1):106. (PMID: 35477569)
Front Immunol. 2022 Jun 17;13:910490. (PMID: 35784306)
Int J Gen Med. 2022 Mar 19;15:3199-3213. (PMID: 35342302)
Mol Cell. 2020 Jun 18;78(6):1019-1033. (PMID: 32559423)
Lancet. 2018 Aug 4;392(10145):432-446. (PMID: 30060998)
Cancer Discov. 2020 Feb;10(2):254-269. (PMID: 31796433)
Front Cell Dev Biol. 2022 Apr 25;10:862493. (PMID: 35547808)
Crit Rev Oncol Hematol. 2022 Apr;172:103641. (PMID: 35189327)
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96. (PMID: 33123732)
J Control Release. 2022 Jan;341:498-510. (PMID: 34883139)
Genes Dis. 2022 Jan;9(1):12-27. (PMID: 34514075)
Clin Cancer Res. 2018 Aug 15;24(16):3792-3802. (PMID: 29593027)
Hepatology. 2019 Jul;70(1):168-183. (PMID: 30411378)
Cancer Lett. 2020 Feb 1;470:126-133. (PMID: 31730903)
Signal Transduct Target Ther. 2021 Mar 29;6(1):128. (PMID: 33776057)
N Engl J Med. 2015 Jun 25;372(26):2499-508. (PMID: 26061753)
Nat Med. 2013 Oct;19(10):1264-72. (PMID: 24056773)
Front Genet. 2022 Jan 07;12:781538. (PMID: 35069683)
Neurologist. 2006 Nov;12(6):279-92. (PMID: 17122724)
J Natl Cancer Inst. 2014 Sep 01;106(8):dju200. (PMID: 25178695)
Cancer Res. 2018 Dec 1;78(23):6575-6580. (PMID: 30154154)
Cytokine Growth Factor Rev. 2017 Apr;34:15-26. (PMID: 28233643)
Oncol Res. 2019 May 7;27(5):557-564. (PMID: 29769161)
Adv Exp Med Biol. 2012;746:42-52. (PMID: 22639158)
Mol Cell. 2021 Nov 18;81(22):4579-4590. (PMID: 34562371)
Nat Commun. 2017 Jun 01;8:15080. (PMID: 28569747)
Cancer Lett. 2020 Apr 28;476:1-12. (PMID: 32044356)
Cells. 2022 Dec 09;11(24):. (PMID: 36552744)
Oncol Lett. 2017 Mar;13(3):1761-1766. (PMID: 28454321)
J Clin Invest. 2023 Jan 17;133(2):. (PMID: 36647828)
Nature. 2016 Dec 1;540(7631):150. (PMID: 27706141)
Theranostics. 2019 May 26;9(12):3595-3607. (PMID: 31281500)
Mol Cancer. 2020 Feb 27;19(1):41. (PMID: 32103760)
Nature. 2015 Oct 29;526(7575):660-5. (PMID: 26375003)
PLoS One. 2019 May 10;14(5):e0216825. (PMID: 31075138)
Cancer Res. 2000 Jan 15;60(2):417-24. (PMID: 10667596)
Neural Regen Res. 2012 May 5;7(13):1013-9. (PMID: 25722690)
Front Bioeng Biotechnol. 2020 Jun 30;8:592. (PMID: 32695752)
J Cancer Res Clin Oncol. 2015 Apr;141(4):575-89. (PMID: 25005789)
Genome Res. 2020 Feb;30(2):155-163. (PMID: 31953347)
Nat Commun. 2022 Oct 29;13(1):6483. (PMID: 36309495)
Acta Neuropathol. 2016 Jun;131(6):803-20. (PMID: 27157931)
Sci Rep. 2018 Dec 7;8(1):17705. (PMID: 30531914)
Immunol Rev. 2017 Mar;276(1):112-120. (PMID: 28258695)
Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2111003119. (PMID: 35787058)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
Front Immunol. 2022 Feb 23;13:842069. (PMID: 35281041)
معلومات مُعتمدة: 32090030 National Natural Science Foundation of China; 2017B030301016 Science and Technology Program of Guangdong Province in China; 2021A1515011126 Guangdong Basic and Applied Basic Research Foundation
فهرسة مساهمة: Keywords: CASP4; Chemotherapy; Glioma; Immunotherapy; Pyroptosis
المشرفين على المادة: EC 3.4.22.- (Caspases, Initiator)
EC 3.4.22.- (CASP4 protein, human)
0 (Biomarkers, Tumor)
تواريخ الأحداث: Date Created: 20240729 Date Completed: 20240729 Latest Revision: 20240906
رمز التحديث: 20240906
مُعرف محوري في PubMed: PMC11286837
DOI: 10.1038/s41598-024-65018-z
PMID: 39075190
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-024-65018-z